Evidence map›Paper›PMID 33628210›Full record

ArticleFrontiers in immunology2021

Comparative Cell Surface Proteomic Analysis of the Primary Human T Cell and Monocyte Responses to Type I Interferon.

Lior Soday, Martin Potts, Leah M Hunter, Benjamin J Ravenhill, Jack W Houghton, James C Williamson, Robin Antrobus, Mark R Wills, Nicholas J Matheson, Michael P Weekes

Open access · goldAbstract readComparative Study
In one paragraph

Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.0field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. CD169 Defines Activated CD14Frontiers in immunology · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Lior SodayCambridge Institute for Medical Research, University of Cambridge, Cambridge, United Kingdom.
Martin PottsCambridge Institute for Medical Research, University of Cambridge, Cambridge, United Kingdom.
Leah M HunterCambridge Institute for Medical Research, University of Cambridge, Cambridge, United Kingdom.
Benjamin J RavenhillCambridge Institute for Medical Research, University of Cambridge, Cambridge, United Kingdom.
Jack W HoughtonCambridge Institute for Medical Research, University of Cambridge, Cambridge, United Kingdom.
James C WilliamsonCambridge Institute for Medical Research, University of Cambridge, Cambridge, United Kingdom.
Robin AntrobusCambridge Institute for Medical Research, University of Cambridge, Cambridge, United Kingdom.
Mark R WillsDepartment of Medicine, University of Cambridge, Addenbrooke's Hospital, Cambridge, United Kingdom.
Nicholas J MathesonCambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), University of Cambridge, Cambridge, United Kingdom.
Michael P WeekesCambridge Institute for Medical Research, University of Cambridge, Cambridge, United Kingdom.
University of Cambridge · GBAddenbrooke's Hospital · GB

Funding

Medical Research Council MR/P008801/1Medical Research Council MR/S00081X/1Wellcome TrustWellcome Trust 108070/Z/15/ZWellcome Trust 109078/Z/15/ZWellcome Trust 203747/Z/16/ZWellcome Trust 220015/Z/19/Z
6 · The paper itself

Abstract

The cellular response to interferon (IFN) is essential for antiviral immunity, IFN-based therapy and IFN-related disease. The plasma membrane (PM) provides a critical interface between the cell and its environment, and is the initial portal of entry for viruses. Nonetheless, the effect of IFN on PM proteins is surprisingly poorly understood, and has not been systematically investigated in primary immune cells. Here, we use multiplexed proteomics to quantify IFNα2a-stimulated PM protein changes in primary human CD14+ monocytes and CD4+ T cells from five donors, quantifying 606 and 482 PM proteins respectively. Comparison of cell surface proteomes revealed a remarkable invariance between donors in the overall composition of the cell surface from each cell type, but a marked donor-to-donor variability in the effects of IFNα2a. Furthermore, whereas only 2.7% of quantified proteins were consistently upregulated by IFNα2a at the surface of CD4+ T cells, 6.8% of proteins were consistently upregulated in primary monocytes, suggesting that the magnitude of the IFNα2a response varies according to cell type. Among these differentially regulated proteins, we found the viral target Endothelin-converting enzyme 1 (ECE1) to be an IFNα2a-stimulated protein exclusively upregulated at the surface of CD4+ T cells. We therefore provide a comprehensive map of the cell surface of IFNα2a-stimulated primary human immune cells, including previously uncharacterized interferon stimulated genes (ISGs) and candidate antiviral factors.

Indexed as

CD4-Positive T-LymphocytesEndothelin-Converting EnzymesHumansInterferon-alphaMonocytesProteomicsECE1 protein, humanEndothelin-Converting EnzymesIFNA2 protein, humanInterferon-alphaantiviral restrictincell surfaceleukocytesmonocyteplasma membranequantitative proteomicsT celltype I interferon (IFN)

Identifiers

PMID33628210
PMCPMC7897682
OpenAlexW3127306168

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.